{
  "personality": null,
  "timestamp": "2025-09-25T04:41:46.831449",
  "category": "Health",
  "news_summary": "Recent advancements in gene therapy, AI-driven medical technology, and innovative treatments are accelerating healing, promoting significant weight loss, and uncovering genetic secrets to longevity.",
  "news_summary_fr": "Les récentes avancées en matière de thérapie génique, de technologie médicale pilotée par l'IA et de traitements innovants accélèrent la guérison, favorisent une perte de poids significative et dévoilent les secrets génétiques de la longévité.",
  "news_summary_es": "Los recientes avances en terapia génica, tecnología médica impulsada por IA y tratamientos innovadores están acelerando la curación, favoreciendo una pérdida de peso significativa y descubriendo secretos genéticos para la longevidad.",
  "articles": [
    {
      "title": "Huntington’s disease breakthrough: what to know about the gene therapy",
      "summary": "Huntington’s disease has been successfully treated for the first time using a gene therapy, which may be available in the US as soon as next year",
      "content": "Huntington’s disease has been successfully treated for the first time using a gene therapy, which may be available in the US as soon as next year\n\nThe caudate nucleus is one of the brain regions the gene therapy targets KATERYNA KON/SCIENCE PHOTO LIBRARY\n\nAn experimental gene therapy has become the first treatment to successfully slow the progression of Huntington’s disease. While the findings are still preliminary, the approach could be a major breakthrough and may even lead to new therapies for other neurodegenerative conditions, like Parkinson’s and Alzheimer’s.\n\nHow does the therapy work?\n\nThe treatment, called AMT-130, targets abnormal proteins in the brain that are responsible for the progression of Huntington’s disease. People with the condition have a genetic mutation that causes the normally-benign huntingtin protein to accumulate in toxic clumps inside brain cells, ultimately killing them. Over time, this leads to memory loss, difficulty walking, slurred speech and other symptoms.\n\nThe experimental therapy, developed by the Dutch biotechnology company uniQure, stops the production of these mutant proteins. It does so by delivering genetic material to brain cells packaged inside a harmless virus. This material then directs cells to produce a small genetic molecule, called microRNA, which is designed to intercept and disable the instructions for producing the toxic protein. Think of it like a molecular stop signal.\n\nAdvertisement\n\nHow and where is the treatment delivered?\n\nThe treatment targets two brain regions first impacted by Huntington’s disease: the caudate nucleus and the putamen. Both are located deep inside the brain, so doctors use real-time brain scans to guide a thin catheter into them. The entire procedure takes 12 to 18 hours. One injection seems to be enough to permanently lower levels of mutant huntingtin in the brain.\n\nHow effective is the gene therapy?\n\nPreliminary results released by uniQure suggest the gene therapy slows the progression of Huntington’s disease by about 75 per cent.\n\nFree newsletter Sign up to Health Check Expert insight and news on scientific developments in health, nutrition and fitness, every Saturday. Sign up to newsletter\n\nThe finding comes from a clinical trial led by Sarah Tabrizi at University College London and her colleagues, in which 17 people with Huntington’s received a high dose of the treatment. Three years later, the researchers compared declines in cognition, movement and daily functioning with those of similar, untreated individuals. Declines that would normally be seen in one year of disease progression occurred in the treated patients over four years on average, Tabrizi told BBC News. Those who received the treatment also saw lower levels of a protein indicative of brain damage in their cerebrospinal fluid, further indicating the gene therapy slows Huntington’s progression.\n\n“These findings reinforce our conviction that AMT-130 has the potential to fundamentally transform the treatment landscape for Huntington’s disease,” said Walid Abid-Saab at uniQure in a statement.\n\nAre there any side effects?\n\nWhile uniQure hasn’t published complete data on the therapy’s side effects, it said so far the drug appears to be safe and well-tolerated. The most common side effects were headaches and confusion, which either resolved without treatment or with steroids to reduce inflammation.\n\nWhen will the therapy become available?\n\nIn a press release, uniQure said it expects to submit an application to the US Food and Drug Administration early next year, and, pending approval, the product could launch before 2027.\n\n“However, it is still early days and a lot more testing is needed to see if there are side-effects of this new gene therapy, how long the benefits last and how well it works in the long term,” said Zofia Miedzybrodzka at the University of Aberdeen in the UK in a statement.\n\nCould this approach help treat other brain conditions?\n\nIf this gene therapy ultimately proves successful, it could lead to the development of similar therapies for other neurodegenerative conditions, such as Parkinson’s disease or other types of dementia, said David Rubinsztein at the University of Cambridge in a statement. Researchers would just have to tweak the genetic material so it targets the toxic proteins that drive those conditions. “This could be a major breakthrough,” he said.",
      "url": "https://www.newscientist.com/article/2497677-huntingtons-disease-breakthrough-what-to-know-about-the-gene-therapy/?utm_campaign=RSS%7CNSNS&utm_source=NSNS&utm_medium=RSS&utm_content=home",
      "source": "New Scientist - Home",
      "published": "2025-09-24",
      "sentiment_score": 0.95,
      "reasoning": "The article reports a major medical breakthrough with the first successful gene therapy treatment that significantly slows Huntington’s disease progression, offering hope for patients and potential applications to other neurodegenerative diseases. The therapy has demonstrated substantial preliminary efficacy and safety, with broad implications for public health.",
      "category": "Health",
      "personality_title": "Gene therapy slows Huntington’s disease progression for the first time",
      "personality_presentation": "**Context** – Huntington’s disease is a serious brain illness caused by a genetic mutation. This mutation makes a protein called huntingtin clump inside brain cells, harming them and causing problems like memory loss, trouble walking, and slurred speech. Until now, no treatments could slow down the disease.\n\n**What happened** – A new gene therapy called AMT-130 has been tested in patients and shown to slow Huntington’s disease by about 75%. Developed by a company named uniQure, the therapy uses a harmless virus to deliver genetic instructions to brain cells. These instructions help cells produce a molecule that stops the harmful huntingtin protein from being made. Doctors inject the therapy into two deep parts of the brain, the caudate nucleus and putamen, using brain scans to guide the process.\n\n**Impact** – This is the first time a treatment has significantly slowed Huntington’s disease. In tests, people who received AMT-130 had much slower worsening of thinking, movement, and daily activities compared to those without treatment. The therapy also lowered signs of brain damage. Side effects were mild and temporary, mostly headaches and confusion. This success shows gene therapy can work for brain diseases and might be adapted for others like Parkinson’s or Alzheimer’s.\n\n**What’s next step** – uniQure plans to ask the US Food and Drug Administration for approval next year. If approved, the therapy could be available before 2027. Researchers still need to study how long the benefits last and check for any long-term side effects. They also want to explore if similar gene therapies can help with other brain illnesses.\n\n**One-sentence takeaway** – A new gene therapy has become the first to slow Huntington’s disease, offering a promising treatment option and a potential path for other brain disorders.",
      "personality_title_fr": "La thérapie génique ralentit pour la première fois la progression de la maladie de Huntington",
      "personality_presentation_fr": "**Contexte** – La maladie de Huntington est une grave maladie cérébrale causée par une mutation génétique. Cette mutation fait que la protéine huntingtine s’accumule dans les cellules du cerveau, les endommageant et provoquant des problèmes comme la perte de mémoire, des difficultés à marcher et un langage brouillé. Jusqu’à présent, aucun traitement ne pouvait ralentir la maladie.\n\n**Ce qui s’est passé** – Une nouvelle thérapie génique appelée AMT-130 a été testée sur des patients et a montré qu’elle ralentit la maladie de Huntington d’environ 75 %. Développée par une entreprise nommée uniQure, la thérapie utilise un virus inoffensif pour transmettre des instructions génétiques aux cellules du cerveau. Ces instructions aident les cellules à produire une molécule qui bloque la production de la protéine huntingtine toxique. Les médecins injectent la thérapie dans deux parties profondes du cerveau, le noyau caudé et le putamen, en se guidant grâce à des scanners cérébraux.\n\n**Impact** – C’est la première fois qu’un traitement ralentit significativement la maladie de Huntington. Lors des essais, les personnes traitées avec AMT-130 ont vu leur déclin des capacités mentales, motrices et des activités quotidiennes beaucoup plus lent que celles non traitées. La thérapie a aussi réduit les signes de dommages cérébraux. Les effets secondaires étaient légers et temporaires, principalement des maux de tête et de la confusion. Ce succès montre que la thérapie génique peut fonctionner pour les maladies du cerveau et pourrait être adaptée à d’autres comme Parkinson ou Alzheimer.\n\n**Prochaine étape** – uniQure prévoit de demander l’autorisation de mise sur le marché à la FDA aux États-Unis l’année prochaine. Si elle est approuvée, la thérapie pourrait être disponible avant 2027. Les chercheurs doivent encore étudier la durée des bénéfices et vérifier les effets secondaires à long terme. Ils souhaitent aussi explorer si des thérapies géniques similaires peuvent aider d’autres maladies cérébrales.\n\n**Résumé en une phrase** – Une nouvelle thérapie génique est la première à ralentir la maladie de Huntington, offrant une option de traitement prometteuse et une voie possible pour d’autres troubles cérébraux.",
      "personality_title_es": "Terapia génica frena por primera vez el avance de la enfermedad de Huntington",
      "personality_presentation_es": "**Contexto** – La enfermedad de Huntington es una grave enfermedad cerebral causada por una mutación genética. Esta mutación hace que una proteína llamada huntingtina se acumule dentro de las células del cerebro, dañándolas y causando problemas como pérdida de memoria, dificultad para caminar y habla arrastrada. Hasta ahora, no había tratamientos que pudieran frenar la enfermedad.\n\n**Qué sucedió** – Una nueva terapia génica llamada AMT-130 se probó en pacientes y mostró que reduce el avance de la enfermedad de Huntington en aproximadamente un 75 %. Desarrollada por la empresa uniQure, la terapia usa un virus inofensivo para entregar instrucciones genéticas a las células del cerebro. Estas instrucciones hacen que las células produzcan una molécula que detiene la producción de la proteína huntingtina tóxica. Los médicos inyectan la terapia en dos partes profundas del cerebro, el núcleo caudado y el putamen, guiándose con escáneres cerebrales.\n\n**Impacto** – Es la primera vez que un tratamiento frena significativamente la enfermedad de Huntington. En las pruebas, las personas que recibieron AMT-130 tuvieron un deterioro mucho más lento en pensamiento, movimiento y actividades diarias en comparación con quienes no recibieron tratamiento. La terapia también redujo señales de daño cerebral. Los efectos secundarios fueron leves y temporales, principalmente dolores de cabeza y confusión. Este éxito muestra que la terapia génica puede funcionar para enfermedades cerebrales y podría adaptarse para otras como Parkinson o Alzheimer.\n\n**Próximo paso** – uniQure planea solicitar la aprobación de la Administración de Alimentos y Medicamentos de EE. UU. (FDA) el próximo año. Si se aprueba, la terapia podría estar disponible antes de 2027. Los investigadores aún deben estudiar cuánto duran los beneficios y revisar posibles efectos secundarios a largo plazo. También quieren explorar si terapias genéticas similares pueden ayudar con otras enfermedades cerebrales.\n\n**Resumen en una frase** – Una nueva terapia génica es la primera en frenar la enfermedad de Huntington, ofreciendo una opción prometedora y un camino posible para otros trastornos cerebrales.",
      "image_url": "public/images/news_image_Huntingtons-disease-breakthrough-what-to-know-abou.png",
      "image_prompt": "A detailed, warm painting of a stylized human brain section highlighting the caudate nucleus and putamen as glowing, gently illuminated areas, with delicate, flowing strands of genetic material (microRNA) weaving through and softly silencing toxic protein clusters represented by dark, tangled knots being gently unraveled and dispersed."
    },
    {
      "title": "Scientists reveal pill that helps shed 20% of body weight",
      "summary": "A massive international study has shown that the experimental oral obesity drug orforglipron can help patients shed over 10% of their body weight, with nearly one in five losing 20% or more. Unlike most GLP-1 agonists that require injections, orforglipron comes as a once-daily pill, potentially making weight-loss treatment more accessible.",
      "content": "New research presented at the Annual Meeting of the European Association for the Study of Diabetes in Vienna, Austria (Sept 15-19) and simultaneously published in NEJM shows that daily treatment with the new once-daily GLP-1 agonist orforglipron results in substantial weight loss in people living with obesity that do not have type 2 diabetes. The study is by Dr Sean Wharton, McMaster University, Hamilton, ON, Canada and Wharton Weight Management Clinic, Burlington, ON, Canada, and colleagues. The study is sponsored by Eli Lilly, the manufacturer of orforglipron.\n\nOrforglipron is a small-molecule, oral glucagon-like peptide-1 (GLP-1) receptor agonist. In this phase 3, multinational, randomised, double-blind trial, the authors examined the safety and efficacy of once-daily orforglipron at doses of 6 mg, 12 mg, or 36 mg, as compared with placebo (assigned in a 3:3:3:4 ratio) as an adjunct to healthy diet and physical activity for 72 weeks. All the patients had obesity but not diabetes. The primary end point was the percent change in body weight from baseline to week 72.\n\nA total of 3127 patients in 9 countries / jurisdictions (USA, China, Brazil, India, Japan, South Korea, Spain, Slovakia and Taiwan) underwent randomisation. The mean relative change in body weight from baseline to week 72 was −7.5% with 6 mg of orforglipron, −8.4% with 12 mg of orforglipron, and −11.2% with 36 mg of orforglipron, as compared with −2.1% with placebo.\n\nAmong the patients in the orforglipron 36 mg group, 54.6% had reduction of 10% or more of body weight, 36.0% had a reduction of 15% or more, and 18.4% had a reduction of 20% or more, as compared with 12.9%, 5.9%, and 2.8% of the patients, respectively, in the placebo group.\n\nOther outcomes such as waist circumference, systolic blood pressure, triglyceride levels, and non-HDL cholesterol levels significantly improved with orforglipron treatment (see table 3 full paper). Adverse events (see table 4) resulted in treatment discontinuation in 5.3% to 10.3% of the patients in the orforglipron groups and in 2.7% of those in the placebo group. The most common adverse events with orforglipron were gastrointestinal effects, which were mostly mild to moderate, consistent with the GLP-1 class of medications.\n\nThe authors note that the use of medications such as GLP-1 receptor agonists (such as semaglutide) are reported to result in mean weight reductions of approximately 15% to above 20% and have shown additional health benefits, including decreased cardiovascular risk. However, most available GLP-1 based medications are administered as a subcutaneous injection, which may limit treatment initiation and adherence.\n\nThe authors say: “After 72 weeks of treatment, all the patients in the three orforglipron groups had a significant and clinically meaningful dose-dependent reduction in body weight. The patients who received the highest dose of orforglipron had an average 11.2% weight reduction; more than one third had a reduction of at least 15%, and nearly one fifth had a reduction of at least 20%. All measured cardiometabolic levels improved with orforglipron treatment as compared with placebo… A weight reduction of 10% or more is a recognised therapeutic threshold, one that has been linked to meaningful cardiometabolic benefits. In our current trial, patients who received orforglipron had a mean weight reduction of as much as 11.2%, and such reductions were associated with improvements in levels of systolic and diastolic blood pressure, as well as blood fats, blood sugar profiles, and high-sensitivity C-reactive protein – a marker of systemic inflammation.”\n\nThe authors note the trial’s limitations include the lack of comparison with currently approved obesity-management medications, the use of cutoffs for BMI inclusion criteria that have been developed in White populations and that exclude patients with lower BMI values who may also have adiposity-related risks, and the increasing availability of obesity-management medications, which could have an effect on treatment adherence and efficacy results. The strengths of the trial include a highly diverse, large population from nine countries and jurisdictions on four continents - including more than 35% enrolment of men.\n\nThey conclude: “In patients with obesity, the use of orforglipron resulted in statistically and clinically significant weight reductions and an adverse-event profile that was consistent with findings regarding other GLP-1 receptor agonists.”\n\nDr Wharton adds: “This could mean an expansion of obesity interventions to groups who are currently excluded due to the cost of and lack of access to injectable medications.”\n\nOrforglipron is not yet approved by the US Food and Drug Administration (FDA) or other similar agencies worldwide.",
      "url": "https://www.sciencedaily.com/releases/2025/09/250924012248.htm",
      "source": "Latest Science News -- ScienceDaily",
      "published": "2025-09-25",
      "sentiment_score": 0.9,
      "reasoning": "The article reports on a significant medical breakthrough: an oral obesity drug that enables substantial weight loss with broad, meaningful health benefits. The large multinational phase 3 trial demonstrates clinically significant weight reductions and cardiometabolic improvements, potentially expanding accessible obesity treatment beyond injectable drugs. The study's scale, diversity, and detailed results provide strong substance and real-world impact.",
      "category": "Health",
      "personality_title": "New pill helps people with obesity lose up to 20% of their body weight",
      "personality_presentation": "**Context** – Obesity affects millions of people worldwide and can lead to serious health problems. Most medicines that help with weight loss need to be injected, which some people find difficult or unpleasant.\n\n**What happened** – Scientists tested a new pill called orforglipron that people take once a day. In a large study with over 3,000 participants from nine countries, those taking the highest dose lost an average of 11.2% of their body weight after 72 weeks. Nearly one in five lost 20% or more. The study also found improvements in blood pressure, cholesterol, and other health markers. The pill caused some mild stomach problems but was generally safe.\n\n**Impact** – This is important because orforglipron is the first pill of its kind that can help people lose a lot of weight without injections. Losing 10% or more of body weight can improve heart health and reduce risks of diseases. Having a pill option could make weight-loss treatment easier to access and use for many people.\n\n**What's next step** – Orforglipron still needs approval from health authorities like the US Food and Drug Administration before it can be widely sold. Researchers will also compare it to other weight-loss medicines and continue checking its long-term safety and benefits.\n\n**One-sentence takeaway** – A new daily pill called orforglipron shows promise in helping people with obesity lose significant weight and improve their health without needing injections.",
      "personality_title_fr": "Une nouvelle pilule aide les personnes obèses à perdre jusqu'à 20 % de leur poids corporel",
      "personality_presentation_fr": "**Contexte** – L'obésité touche des millions de personnes dans le monde et peut entraîner de graves problèmes de santé. La plupart des médicaments pour perdre du poids nécessitent des injections, ce que certaines personnes trouvent difficile ou désagréable.\n\n**Ce qui s'est passé** – Des scientifiques ont testé une nouvelle pilule appelée orforglipron, prise une fois par jour. Dans une grande étude avec plus de 3 000 participants de neuf pays, ceux qui ont pris la dose la plus élevée ont perdu en moyenne 11,2 % de leur poids après 72 semaines. Près d'une personne sur cinq a perdu 20 % ou plus. L'étude a aussi montré des améliorations de la tension artérielle, du cholestérol et d'autres signes de santé. La pilule a causé quelques troubles digestifs légers mais était généralement sûre.\n\n**Impact** – Cela est important car orforglipron est la première pilule de ce type qui aide à perdre beaucoup de poids sans injections. Perdre 10 % ou plus de son poids peut améliorer la santé du cœur et réduire les risques de maladies. Avoir une option en pilule pourrait rendre le traitement plus facile à obtenir et à utiliser pour beaucoup de personnes.\n\n**Prochaine étape** – Orforglipron doit encore être approuvé par les autorités sanitaires comme la FDA aux États-Unis avant d'être vendu largement. Les chercheurs vont aussi le comparer à d'autres médicaments pour la perte de poids et continuer à vérifier sa sécurité et ses bienfaits sur le long terme.\n\n**Résumé en une phrase** – Une nouvelle pilule quotidienne, orforglipron, montre qu'elle peut aider les personnes obèses à perdre beaucoup de poids et à améliorer leur santé sans avoir besoin d'injections.",
      "personality_title_es": "Nueva píldora ayuda a personas con obesidad a perder hasta un 20 % de su peso corporal",
      "personality_presentation_es": "**Contexto** – La obesidad afecta a millones de personas en todo el mundo y puede causar problemas graves de salud. La mayoría de los medicamentos para bajar de peso requieren inyecciones, lo que algunas personas encuentran difícil o incómodo.\n\n**Qué pasó** – Científicos probaron una nueva píldora llamada orforglipron, que se toma una vez al día. En un gran estudio con más de 3,000 participantes de nueve países, quienes tomaron la dosis más alta perdieron en promedio un 11.2 % de su peso después de 72 semanas. Casi uno de cada cinco perdió un 20 % o más. El estudio también encontró mejoras en la presión arterial, colesterol y otros indicadores de salud. La píldora causó algunos problemas leves en el estómago pero fue segura en general.\n\n**Impacto** – Esto es importante porque orforglipron es la primera píldora de este tipo que ayuda a perder mucho peso sin inyecciones. Perder un 10 % o más del peso corporal puede mejorar la salud del corazón y reducir riesgos de enfermedades. Tener una opción en píldora podría facilitar el acceso y uso del tratamiento para muchas personas.\n\n**Próximo paso** – Orforglipron aún necesita la aprobación de autoridades sanitarias como la Administración de Alimentos y Medicamentos de EE. UU. antes de poder venderse ampliamente. Los investigadores también lo compararán con otros medicamentos para bajar de peso y seguirán estudiando su seguridad y beneficios a largo plazo.\n\n**Conclusión en una frase** – Una nueva píldora diaria llamada orforglipron muestra potencial para ayudar a personas con obesidad a perder peso significativo y mejorar su salud sin necesidad de inyecciones.",
      "image_url": "public/images/news_image_Scientists-reveal-pill-that-helps-shed-20-of-body-.png",
      "image_prompt": "A warm and detailed painting of a gently curved, oversized pill dissolving into a flowing river of golden light that gradually transforms into a series of shrinking silhouettes symbolizing weight loss, set against a soft, natural color palette with abstract shapes evoking global unity and health improvement."
    },
    {
      "title": "AI-powered smart bandage heals wounds 25% faster",
      "summary": "A new wearable device, a-Heal, combines AI, imaging, and bioelectronics to speed up wound recovery. It continuously monitors wounds, diagnoses healing stages, and applies personalized treatments like medicine or electric fields. Preclinical tests showed healing about 25% faster than standard care, highlighting potential for chronic wound therapy.",
      "content": "As a wound heals, it goes through several stages: clotting to stop bleeding, immune system response, scabbing, and scarring.\n\nA wearable device called \"a-Heal,\" designed by engineers at the University of California, Santa Cruz, aims to optimize each stage of the process. The system uses a tiny camera and AI to detect the stage of healing and deliver a treatment in the form of medication or an electric field. The system responds to the unique healing process of the patient, offering personalized treatment.\n\nThe portable, wireless device could make wound therapy more accessible to patients in remote areas or with limited mobility. Initial preclinical results, published in the journal npj Biomedical Innovations, show the device successfully speeds up the healing process.\n\nDesigning a-Heal\n\nA team of UC Santa Cruz and UC Davis researchers, sponsored by the DARPA-BETR program and led by UC Santa Cruz Baskin Engineering Endowed Chair and Professor of Electrical and Computer Engineering (ECE) Marco Rolandi, designed a device that combines a camera, bioelectronics, and AI for faster wound healing. The integration in one device makes it a \"closed-loop system\" -- one of the firsts of its kind for wound healing as far as the researchers are aware.\n\n\"Our system takes all the cues from the body, and with external interventions, it optimizes the healing progress,\" Rolandi said.\n\nThe device uses an onboard camera, developed by fellow Associate Professor of ECE Mircea Teodorescu and described in a Communications Biology study, to take photos of the wound every two hours. The photos are fed into a machine learning (ML) model, developed by Associate Professor of Applied Mathematics Marcella Gomez, which the researchers call the \"AI physician\" running on a nearby computer.\n\n\"It's essentially a microscope in a bandage,\" Teodorescu said. \"Individual images say little, but over time, continuous imaging lets AI spot trends, wound healing stages, flag issues, and suggest treatments.\"\n\nThe AI physician uses the image to diagnose the wound stage and compares that to where the wound should be along a timeline of optimal wound healing. If the image reveals a lag, the ML model applies a treatment: either medicine, delivered via bioelectronics; or an electric field, which can enhance cell migration toward wound closure.\n\nThe treatment topically delivered through the device is fluoxetine, a selective serotonin reuptake inhibitor which controls serotonin levels in the wound and improves healing by decreasing inflammation and increasing wound tissue closure. The dose, determined by preclinical studies by the Isseroff group at UC Davis group to optimize healing, is administered by bioelectronic actuators on the device, developed by Rolandi. An electric field, optimized to improve healing and developed by prior work of the UC Davis' Min Zhao and Roslyn Rivkah Isseroff, is also delivered through the device.\n\nThe AI physician determines the optimal dosage of medication to deliver and the magnitude of the applied electric field. After the therapy has been applied for a certain period of time, the camera takes another image, and the process starts again.\n\nWhile in use, the device transmits images and data such as healing rate to a secure web interface, so a human physician can intervene manually and fine-tune treatment as needed. The device attaches directly to a commercially available bandage for convenient and secure use.\n\nTo assess the potential for clinical use, the UC Davis team tested the device in preclinical wound models. In these studies, wounds treated with a-Heal followed a healing trajectory about 25% faster than standard of care. These findings highlight the promise of the technology not only for accelerating closure of acute wounds, but also for jump-starting stalled healing in chronic wounds.\n\nAI reinforcement\n\nThe AI model used for this system, which was led by Assistant Professor of Applied Mathematics Marcella Gomez, uses a reinforcement learning approach, described in a study in the journal Bioengineering, to mimic the diagnostic approach used by physicians.\n\nReinforcement learning is a technique in which a model is designed to fulfill a specific end goal, learning through trial and error how to best achieve that goal. In this context, the model is given a goal of minimizing time to wound closure, and is rewarded for making progress toward that goal. It continually learns from the patient and adapts its treatment approach.\n\nThe reinforcement learning model is guided by an algorithm that Gomez and her students created called Deep Mapper, described in a preprint study, which processes wound images to quantify the stage of healing in comparison to normal progression, mapping it along the trajectory of healing. As time passes with the device on a wound, it learns a linear dynamic model of the past healing and uses that to forecast how the healing will continue to progress.\n\n\"It's not enough to just have the image, you need to process that and put it into context. Then, you can apply the feedback control,\" Gomez said.\n\nThis technique makes it possible for the algorithm to learn in real-time the impact of the drug or electric field on healing, and guides the reinforcement learning model's iterative decision making on how to adjust the drug concentration or electric-field strength.\n\nNow, the research team is exploring the potential for this device to improve healing of chronic and infected wounds.\n\nAdditional publications related to this work can be found linked here.\n\nThis research was supported by the Defense Advanced Research Projects Agency and the Advanced Research Projects Agency for Health.",
      "url": "https://www.sciencedaily.com/releases/2025/09/250924012232.htm",
      "source": "Latest Science News -- ScienceDaily",
      "published": "2025-09-24",
      "sentiment_score": 0.9,
      "reasoning": "The article reports on a significant technological breakthrough in wound care that combines AI, imaging, and bioelectronics to accelerate healing by 25%. This innovation has broad potential health benefits, especially for chronic wound patients and those with limited access to care, and is supported by detailed research and preclinical results.",
      "category": "Health",
      "personality_title": "AI-powered smart bandage speeds up wound healing by 25%",
      "personality_presentation": "**Context** – Wounds heal in several stages like clotting, immune response, scabbing, and scarring. Healing can sometimes be slow, especially for chronic wounds, which affect many people and need better treatments.\n\n**What happened** – Engineers at the University of California, Santa Cruz, created a wearable device called \"a-Heal\" that uses a small camera and artificial intelligence (AI) to watch wounds closely. It checks the wound every two hours, figures out what stage the healing is in, and then delivers medicine or electric fields to help the wound heal faster. This device is wireless and attaches to a regular bandage.\n\n**Impact** – Tests on animals showed that wounds treated with a-Heal healed about 25% faster than usual methods. The AI adjusts treatment based on how the wound is doing, making it personalized for each patient. This could help people who live far from hospitals or have trouble moving around get better care at home.\n\n**What's next step** – Researchers plan to test a-Heal on chronic and infected wounds to see if it can help even those that are hard to heal. They also want to improve the AI and treatments based on new data from patients.\n\n**One-sentence takeaway** – A smart bandage using AI and bioelectronics can speed up wound healing by 25%, offering new hope for better, personalized care.\n",
      "personality_title_fr": "Un pansement intelligent piloté par IA accélère la cicatrisation de 25 %",
      "personality_presentation_fr": "**Contexte** – La cicatrisation des blessures se fait en plusieurs étapes : coagulation, réaction immunitaire, formation de croûtes et cicatrices. Ce processus peut être lent, surtout pour les blessures chroniques qui nécessitent de meilleurs traitements.\n\n**Ce qui s'est passé** – Des ingénieurs de l'université de Californie à Santa Cruz ont créé un dispositif portable appelé « a-Heal » qui utilise une petite caméra et l'intelligence artificielle (IA) pour surveiller les blessures. Il prend des photos toutes les deux heures, identifie l'étape de cicatrisation, puis applique un traitement par médicament ou champ électrique pour accélérer la guérison. Ce dispositif sans fil se fixe sur un pansement classique.\n\n**Impact** – Des tests précliniques ont montré que les blessures traitées avec a-Heal guérissaient environ 25 % plus vite que les méthodes habituelles. L'IA ajuste le traitement en fonction de l'évolution de la blessure, offrant un soin personnalisé. Cela pourrait aider les personnes éloignées des hôpitaux ou à mobilité réduite à recevoir des soins plus facilement.\n\n**Étapes suivantes** – Les chercheurs veulent maintenant tester a-Heal sur des blessures chroniques et infectées pour voir s’il peut aussi aider ce type de plaies difficiles à soigner. Ils souhaitent aussi améliorer l’IA et les traitements grâce aux nouvelles données des patients.\n\n**Résumé en une phrase** – Un pansement intelligent combinant IA et bioélectronique peut accélérer la cicatrisation de 25 %, ouvrant la voie à des soins personnalisés améliorés.\n",
      "personality_title_es": "Un vendaje inteligente con IA acelera la cicatrización de heridas en un 25%",
      "personality_presentation_es": "**Contexto** – Las heridas se curan en varias etapas: coagulación, respuesta inmunitaria, formación de costras y cicatrices. A veces, este proceso es lento, especialmente en heridas crónicas que necesitan mejores tratamientos.\n\n**Qué pasó** – Un equipo de ingenieros de la Universidad de California en Santa Cruz creó un dispositivo portátil llamado \"a-Heal\" que usa una pequeña cámara y inteligencia artificial (IA) para monitorear las heridas. Toma fotos cada dos horas, identifica la etapa de curación y aplica medicación o campos eléctricos para acelerar la sanación. El dispositivo es inalámbrico y se fija a un vendaje común.\n\n**Impacto** – Pruebas en modelos preclínicos mostraron que las heridas tratadas con a-Heal sanaron un 25 % más rápido que con los métodos tradicionales. La IA ajusta el tratamiento según cómo evoluciona la herida, personalizando la atención. Esto podría ayudar a personas que viven lejos de hospitales o tienen movilidad limitada.\n\n**Próximo paso** – Los investigadores planean probar a-Heal en heridas crónicas e infectadas para ver si también puede ayudar en casos difíciles. También buscan mejorar la IA y los tratamientos con nuevos datos de pacientes.\n\n**Conclusión en una frase** – Un vendaje inteligente que combina IA y bioelectrónica puede acelerar la cicatrización en un 25 %, ofreciendo una atención personalizada mejorada.\n",
      "image_url": "public/images/news_image_AI-powered-smart-bandage-heals-wounds-25-faster.png",
      "image_prompt": "A detailed, warm-toned painting of a stylized, glowing smart bandage gently wrapped around an abstract, softly textured wound area, with delicate, translucent circuits and a tiny camera lens integrated seamlessly into the bandage; subtle electric currents and soft golden light pulses symbolize AI-driven healing and personalized treatment accelerating the natural regenerative process."
    },
    {
      "title": "World’s oldest person had a young microbiome and 'exceptional genome'",
      "summary": "Scientists have studied the genetics and lifestyle factors that enabled María Branyas Morera, officially the oldest person in the world until she died last year, to reach 117 years old",
      "content": "Scientists have studied the genetics and lifestyle factors that enabled María Branyas Morera, officially the oldest person in the world until she died last year, to reach 117 years old\n\nMaría Branyas Morera, pictured with scientist Manel Esteller, took part in a study to help researchers understand her longevity Manel Esteller\n\nBetween 17 January 2023 and 19 August 2024, María Branyas Morera, of Spain, was officially the world’s oldest person, until she died aged 117 years and 168 days. To uncover the secrets of her extraordinary longevity, a team of researchers has done a deep dive into her genetics, microbiome and lifestyle.\n\nWhen Morera was 116 years old, the team collected samples of her blood, saliva and stool, to analyse her genetics. “She had an exceptional genome enriched in variants in genes that are associated with enhanced lifespan in other species, such as dogs, worms and flies,” says team member Manel Esteller at the Josep Carreras Leukaemia Research Institute in Barcelona, Spain.\n\nAdvertisement\n\nMorera, who showed no sign of dementia, also had many gene variants that keep blood lipid levels low, protecting the heart and cognition, says Esteller. “At the same time, she was devoid of gene variants associated with the risk of pathologies such as cancer, Alzheimer’s and metabolic disorders.”\n\nBlood test results also revealed that her lipid metabolism was among the most efficient ever reported, according to the researchers. “Her lipid profile was amazing, with very low cholesterol,” says Esteller. “This was related to her frugal diet and genes that quickly metabolised damaging molecules.”\n\nEsteller says Morera didn’t drink alcohol or smoke, and adhered to a Mediterranean diet, made up of lots of vegetables, fruits, legumes and olive oil. She also ate three servings of plain, sugar-free yoghurt every day.\n\nFree newsletter Sign up to Health Check Expert insight and news on scientific developments in health, nutrition and fitness, every Saturday. Sign up to newsletter\n\nThe team’s tests also suggest that Morera retained an efficient immune system into old age and a gut microbiome characteristic of a much younger individual.\n\nOne of the most “startling” findings was the high levels of Actinobacteriota bacteria in her gut, including the well-known probiotic Bifidobacterium. This typically declines with age, but is elevated in centenarians and supercentenarians, and it is thought to have multiple anti-ageing benefits, such as reducing inflammation.\n\nThe team suspects her yoghurt consumption helped continuously replenish her Bifidobacterium levels. “It shows that maybe a dietary intervention can be associated not only with avoiding obesity and other pathologies, but also with prolonged life, acting through the microbiome gut landscape,” says Esteller.\n\nFinally, the scientists tried to gauge whether Morera’s biological age differed substantially from her chronological age. This was done by creating an epigenetic clock based on her DNA methylation – the process in which DNA adds or removes chemical tags that help switch various genes on and off. “Her biological age was an average 23 years younger than her chronological age, one of the reasons that she was alive,” says Esteller.\n\nPrevious research suggests that supercentenarians can have genetic variants associated with various medical conditions, such as Alzheimer’s disease or heart problems, but somehow have the means to endure them, leading to a long life. “Very few studies are available for supercentenarians. In these [previous ones], only one dimension is studied, e.g. [the] microbiome,” says Esteller. “Our study shows that overcoming such diseases is a combination of good genes plus the other factors: [a] beneficial microbiome, slowed-down biological age shown by a younger epigenome and an efficient immune system, plus the behaviour part – no smoking, no alcohol, low-fat diet, etc.”\n\nRichard Faragher at the University of Brighton in the UK says the study demonstrates how many tests are now available to longevity researchers, but cautions that this is a case report of one individual and there is a “danger that a slightly unusual variant in, for example, a gene can be turned into a scientific ‘just-so story’ about its relevance to ageing”.\n\nInstead, he says there are two main explanations for the survival of very long-lived individuals. “Firstly, that there is something special about them, for example genetically, and secondly, survivorship bias, aka they got lucky,” says Faragher.\n\nTo offer proof against her longevity just being luck, there would need to be evidence that Morera is part of a family in which people are known to be long lived, which isn’t presented in this study, he says.",
      "url": "https://www.newscientist.com/article/2497328-worlds-oldest-person-had-a-young-microbiome-and-exceptional-genome/?utm_campaign=RSS%7CNSNS&utm_source=NSNS&utm_medium=RSS&utm_content=home",
      "source": "New Scientist - Home",
      "published": "2025-09-24",
      "sentiment_score": 0.85,
      "reasoning": "The article reports on a scientific study that identifies genetic, microbiome, and lifestyle factors contributing to exceptional human longevity, providing meaningful insights that could inspire further research and potential health benefits for the broader public.",
      "category": "Health",
      "personality_title": "Scientists uncover genetic and lifestyle secrets behind the world’s oldest person",
      "personality_presentation": "**Context** – María Branyas Morera from Spain was the world’s oldest person until she passed away at 117 years old. Researchers wanted to understand why she lived so long by studying her genes, gut bacteria, and daily habits.\n\n**What happened** – When María was 116, scientists took samples of her blood, saliva, and stool to analyze her DNA and microbiome (the community of bacteria in her gut). They found she had special gene variants linked to long life and a very healthy heart and brain. She also had a gut full of beneficial bacteria usually found in much younger people, likely helped by her daily consumption of plain, sugar-free yogurt. María followed a Mediterranean diet, did not smoke or drink alcohol, and had an immune system that worked well even at an old age.\n\n**Impact** – This study is important because it combined many factors—genes, gut health, immune strength, and lifestyle—to explain why María lived so long and stayed healthy. Her biological age was about 23 years younger than her actual age, showing that her body stayed younger inside. The findings suggest that a mix of good genes and healthy habits can help people live longer and better lives.\n\n**What’s next step** – Researchers hope to study more people like María to see if these findings apply to others. They want to learn how diet and gut bacteria can improve health and possibly slow down aging. This could lead to new ways to help people live longer with fewer diseases.\n\n**One-sentence takeaway** – María Branyas Morera’s long life was supported by a unique combination of healthy genes, youthful gut bacteria, and a careful lifestyle that kept her body younger than her years.",
      "personality_title_fr": "Les secrets génétiques et de mode de vie de la personne la plus âgée du monde révélés",
      "personality_presentation_fr": "**Contexte** – María Branyas Morera, originaire d’Espagne, a été la personne la plus âgée du monde jusqu’à son décès à 117 ans. Des chercheurs ont voulu comprendre pourquoi elle a vécu aussi longtemps en étudiant ses gènes, ses bactéries intestinales et ses habitudes quotidiennes.\n\n**Ce qui s’est passé** – À 116 ans, les scientifiques ont prélevé des échantillons de son sang, de sa salive et de ses selles pour analyser son ADN et son microbiome (l’ensemble des bactéries dans ses intestins). Ils ont découvert qu’elle possédait des variantes génétiques spéciales liées à une longue vie et à un cœur et un cerveau très sains. Elle avait aussi beaucoup de bonnes bactéries intestinales, habituellement présentes chez des personnes beaucoup plus jeunes, probablement grâce à sa consommation quotidienne de yaourt nature sans sucre. María suivait un régime méditerranéen, ne fumait pas et ne buvait pas d’alcool, et son système immunitaire fonctionnait bien même à un âge avancé.\n\n**Impact** – Cette étude est importante car elle a combiné plusieurs facteurs – génétique, santé intestinale, force du système immunitaire et mode de vie – pour expliquer pourquoi María a vécu aussi longtemps en bonne santé. Son âge biologique était environ 23 ans plus jeune que son âge réel, ce qui montre que son corps est resté jeune à l’intérieur. Ces résultats suggèrent qu’un mélange de bons gènes et d’habitudes saines peut aider à vivre plus longtemps et en meilleure santé.\n\n**Prochaines étapes** – Les chercheurs espèrent étudier d’autres personnes comme María pour voir si ces découvertes s’appliquent à d’autres. Ils veulent apprendre comment l’alimentation et les bactéries intestinales peuvent améliorer la santé et peut-être ralentir le vieillissement. Cela pourrait mener à de nouvelles façons d’aider les gens à vivre plus longtemps avec moins de maladies.\n\n**Résumé en une phrase** – La longue vie de María Branyas Morera a été soutenue par une combinaison unique de bons gènes, de bactéries intestinales jeunes et d’un mode de vie sain qui a gardé son corps plus jeune que son âge réel.",
      "personality_title_es": "Científicos descubren secretos genéticos y de estilo de vida de la persona más longeva del mundo",
      "personality_presentation_es": "**Contexto** – María Branyas Morera, de España, fue la persona más vieja del mundo hasta que murió a los 117 años. Los investigadores quisieron entender por qué vivió tanto tiempo estudiando sus genes, bacterias intestinales y hábitos diarios.\n\n**Qué pasó** – Cuando María tenía 116 años, los científicos tomaron muestras de su sangre, saliva y heces para analizar su ADN y microbioma (las bacterias en su intestino). Encontraron que tenía variantes genéticas especiales relacionadas con una vida larga y un corazón y cerebro muy saludables. También tenía muchas bacterias buenas en el intestino, típicas de personas mucho más jóvenes, probablemente por su consumo diario de yogur natural sin azúcar. María seguía una dieta mediterránea, no fumaba ni bebía alcohol, y su sistema inmunológico funcionaba bien incluso a edad avanzada.\n\n**Impacto** – Este estudio es importante porque combinó muchos factores—genes, salud intestinal, fuerza del sistema inmunológico y estilo de vida—para explicar por qué María vivió tanto y se mantuvo saludable. Su edad biológica era unos 23 años menor que su edad real, mostrando que su cuerpo se mantuvo más joven por dentro. Los resultados sugieren que una mezcla de buenos genes y hábitos saludables puede ayudar a vivir más tiempo y con mejor salud.\n\n**Próximo paso** – Los investigadores esperan estudiar a más personas como María para ver si estos hallazgos se aplican a otros. Quieren aprender cómo la dieta y las bacterias del intestino pueden mejorar la salud y posiblemente frenar el envejecimiento. Esto podría llevar a nuevas formas de ayudar a las personas a vivir más tiempo con menos enfermedades.\n\n**Conclusión en una frase** – La larga vida de María Branyas Morera estuvo apoyada por una combinación única de buenos genes, bacterias intestinales jóvenes y un estilo de vida cuidadoso que mantuvo su cuerpo más joven que su edad real.",
      "image_url": "public/images/news_image_Worlds-oldest-person-had-a-young-microbiome-and-ex.png",
      "image_prompt": "A warm, detailed painting of an ancient olive tree with deep roots entwined around glowing DNA strands and vibrant clusters of probiotic bacteria shaped like friendly, abstract shapes nestled in rich Mediterranean soil, surrounded by fresh vegetables, legumes, and bowls of plain yogurt, all rendered in soft, natural earth tones."
    }
  ]
}